Florida Medical Marijuana Sales Hit 12.1B mg of THC in 2026

Sales Volume Positions Florida as Third-Largest U.S. Medical Market

Florida's 12.1 billion mg of THC sold in 2026 year-to-date ranks the state behind only California and Michigan in total medical cannabis volume. The 4.1 million ounces translates to roughly 116,000 kilograms of product moving through the state's 25 licensed Medical Marijuana Treatment Centers and their 600-plus retail locations. At an estimated average wholesale price of $1,200 per pound, the volume represents approximately $550 million in wholesale value. Retail sales for the first seven months top $1.1 billion.

The state's Office of Medical Marijuana Use tracks dispensing in milligrams of THC rather than dollar figures, making Florida one of few states to publish granular cannabinoid-level data. The 12.1 billion mg figure includes all product forms—flower, vapes, edibles, concentrates, and topicals—dispensed to the state's 890,000 active medical cardholders as of July 2026.

Investor Implications: MSO Exposure and November's Adult-Use Vote

The volume growth matters most to the four multi-state operators with dominant Florida footprints: Trulieve, Curaleaf, Verano, and AYR Wellness. Trulieve operates 130 Florida dispensaries and derives an estimated 52% of its total revenue from the state, according to Q1 2026 earnings disclosures. Curaleaf's 60 Florida stores contribute roughly 18% of system-wide sales. For both operators, Florida's medical momentum provides a revenue floor heading into the November 2026 ballot question on adult-use legalization.

If Amendment 3 passes with the required 60% supermajority, existing medical operators convert their infrastructure overnight into adult-use distribution, potentially tripling the addressable market. That's the bull case. The bear scenario? Florida's constitutional amendment requires existing operators to fund the campaign—Trulieve has committed $45 million to the Smart & Safe Florida PAC—and a loss would strand that capital while capping the state at medical-only growth.

Equity analysts at Canaccord Genuity estimate Florida adult-use legalization would add $320 million in annual EBITDA to Trulieve's 2027 run rate, a 28% lift from current projections. That math explains why Trulieve shares have tracked polling on Amendment 3 more closely than federal rescheduling headlines in recent months.

What the Numbers Signal for Q3 Earnings Season

The 12.1 billion mg run rate through July suggests Florida's medical market is on pace for 20-21 billion mg of THC sales in full-year 2026, up roughly 9% year-over-year. Growth has slowed. The state posted a 14% clip in 2025 and 22% expansion in 2024, but market maturation is setting in as patient counts plateau near 900,000. New patient additions have slowed to 3,000-4,000 per month in 2026, down from 8,000-10,000 monthly adds in 2024.

For operators reporting Q3 2026 earnings in November, Florida same-store sales growth will be a key metric. Investors will parse whether per-patient spending is rising—a sign of product mix shift toward higher-margin concentrates and vapes—or flat, which would indicate price compression from oversupply. Wholesale biomass prices have held steady near $1,100-1,300 per pound through 2026, a healthier dynamic than the $600-800 trough seen in mature markets like Colorado and Oregon.

For complete background on Florida's regulatory framework and operator landscape, see the CannIntel topic hub on Florida's medical marijuana program.